Search for authorsSearch for similar articles
76
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      IRF3 and Type I Interferons Fuel a Fatal Response to Myocardial Infarction

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Interferon regulatory factor 3 (IRF3) and type I interferons (IFNs) protect against infections 1 and cancer 2 , but excessive IRF3 activation and type I IFN production cause auto-inflammatory conditions such as Aicardi Goutieres Syndrome 3, 4 and STING-associated vasculopathy of infancy (SAVI) 3 . Myocardial infarction (MI) elicits inflammation 5 , but the dominant molecular drivers of MI-associated inflammation remain unclear. Here, we show that ischemic cell death in the heart fuels a fatal response to myocardial infarction by activating IRF3 and type I IFN production. In mice, single cell RNA-Seq analysis of 4,215 leukocytes isolated from infarcted and non-infarcted hearts revealed that MI provokes activation of an IRF3-interferon axis in a distinct population of interferon inducible cells (IFNICs that were classified as cardiac macrophages). Mice genetically deficient in cGAS, its adaptor STING, IRF3, or the type I interferon receptor IFNAR exhibited impaired interferon stimulated gene (ISG) expression and, in the case of mice deficient in IRF3 or IFNAR, improved survival after MI as compared to controls. Interruption of IRF3-dependent signaling resulted in decreased cardiac expression of inflammatory cytokines and chemokines and decreased cardiac inflammatory cell infiltration, as well as in attenuated ventricular dilation and improved cardiac function. Similarly, treatment of mice with an IFNAR neutralizing antibody after MI ablated the IFN response and improved left ventricular dysfunction and survival. These results identify IRF3 and the type I interferon response as a potential therapeutic target for post-MI cardioprotection.

          SUMMARY

          The massive cell death that occurs during myocardial infarction releases self-DNA and triggers an interferon response in infiltrating leukocytes via a cGAS-STING-IRF3 pathway. In mice subjected to myocardial infarction, genetic disrupton of this pathway or antibody blockade of the type I interferon receptor improved heart function and survival.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

          Spontaneous T cell responses against tumors occur frequently and have prognostic value in patients. The mechanism of innate immune sensing of immunogenic tumors leading to adaptive T cell responses remains undefined, although type I interferons (IFNs) are implicated in this process. We found that spontaneous CD8(+) T cell priming against tumors was defective in mice lacking stimulator of interferon genes complex (STING), but not other innate signaling pathways, suggesting involvement of a cytosolic DNA sensing pathway. In vitro, IFN-? production and dendritic cell activation were triggered by tumor-cell-derived DNA, via cyclic-GMP-AMP synthase (cGAS), STING, and interferon regulatory factor 3 (IRF3). In the tumor microenvironment in vivo, tumor cell DNA was detected within host antigen-presenting cells, which correlated with STING pathway activation and IFN-? production. Our results demonstrate that a major mechanism for innate immune sensing of cancer occurs via the host STING pathway, with major implications for cancer immunotherapy. Copyright © 2014 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The inflammatory response in myocardial injury, repair, and remodelling.

            Myocardial infarction triggers an intense inflammatory response that is essential for cardiac repair, but which is also implicated in the pathogenesis of postinfarction remodelling and heart failure. Signals in the infarcted myocardium activate toll-like receptor signalling, while complement activation and generation of reactive oxygen species induce cytokine and chemokine upregulation. Leukocytes recruited to the infarcted area, remove dead cells and matrix debris by phagocytosis, while preparing the area for scar formation. Timely repression of the inflammatory response is critical for effective healing, and is followed by activation of myofibroblasts that secrete matrix proteins in the infarcted area. Members of the transforming growth factor β family are critically involved in suppression of inflammation and activation of a profibrotic programme. Translation of these concepts to the clinic requires an understanding of the pathophysiological complexity and heterogeneity of postinfarction remodelling in patients with myocardial infarction. Individuals with an overactive and prolonged postinfarction inflammatory response might exhibit left ventricular dilatation and systolic dysfunction and might benefit from targeted anti-IL-1 or anti-chemokine therapies, whereas patients with an exaggerated fibrogenic reaction can develop heart failure with preserved ejection fraction and might require inhibition of the Smad3 (mothers against decapentaplegic homolog 3) cascade. Biomarker-based approaches are needed to identify patients with distinct pathophysiologic responses and to rationally implement inflammation-modulating strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              IFNalpha activates dormant haematopoietic stem cells in vivo.

              Maintenance of the blood system is dependent on dormant haematopoietic stem cells (HSCs) with long-term self-renewal capacity. After injury these cells are induced to proliferate to quickly re-establish homeostasis. The signalling molecules promoting the exit of HSCs out of the dormant stage remain largely unknown. Here we show that in response to treatment of mice with interferon-alpha (IFNalpha), HSCs efficiently exit G(0) and enter an active cell cycle. HSCs respond to IFNalpha treatment by the increased phosphorylation of STAT1 and PKB/Akt (also known as AKT1), the expression of IFNalpha target genes, and the upregulation of stem cell antigen-1 (Sca-1, also known as LY6A). HSCs lacking the IFNalpha/beta receptor (IFNAR), STAT1 (ref. 3) or Sca-1 (ref. 4) are insensitive to IFNalpha stimulation, demonstrating that STAT1 and Sca-1 mediate IFNalpha-induced HSC proliferation. Although dormant HSCs are resistant to the anti-proliferative chemotherapeutic agent 5-fluoro-uracil, HSCs pre-treated (primed) with IFNalpha and thus induced to proliferate are efficiently eliminated by 5-fluoro-uracil exposure in vivo. Conversely, HSCs chronically activated by IFNalpha are functionally compromised and are rapidly out-competed by non-activatable Ifnar(-/-) cells in competitive repopulation assays. Whereas chronic activation of the IFNalpha pathway in HSCs impairs their function, acute IFNalpha treatment promotes the proliferation of dormant HSCs in vivo. These data may help to clarify the so far unexplained clinical effects of IFNalpha on leukaemic cells, and raise the possibility for new applications of type I interferons to target cancer stem cells.
                Bookmark

                Author and article information

                Journal
                9502015
                8791
                Nat Med
                Nat. Med.
                Nature medicine
                1078-8956
                1546-170X
                15 May 2018
                06 November 2017
                December 2017
                23 April 2019
                : 23
                : 12
                : 1481-1487
                Affiliations
                [1 ]Department of Medicine/Cardiology and Bioengineering, University of California San Diego, La Jolla, CA, USA.
                [2 ]Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Simches Research Building, 185 Cambridge Street, Boston, MA, USA.
                [3 ]Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
                [4 ]Harvard College, Cambridge, Massachusetts, USA.
                [5 ]Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA
                [6 ]Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA
                [7 ]Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
                [8 ]Department of Medicine, Cardiovascular Division, University of Massachusetts Medical School, Worcester, USA.
                [9 ]Department of Immunology, University of Massachusetts Medical School, Worcester, MA, USA.
                [10 ]Department of Systems Biology, Harvard Medical School, Boston, MA, USA.
                [11 ]Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.
                Author notes

                Author Contributions K.R.K. and A.D.A. designed and performed the experiments, analyzed the data, and wrote the manuscript; Y.-X.Y. designed and performed experiments, and analyzed data; M.K. performed myocardial infarction on WT , IFNAR −/− , and cGAS −/− mice with T.P.F; Y.S. performed myocardial infarctions on WT and all other mouse strains; A.S. and R.I.S. performed bioinformatics analysis; Y.I. performed histologic analysis; R.P.N.Jr. performed biomolecular analysis; J.D.R. performed echocardiography and data analysis, R.H.K. performed confocal imaging, S.P.A. performed bone marrow derived macrophage experiments, T.M., K.A.F., and P.L. provided guidance on experimental design; and M.N. and R.W. designed experiments, analyzed data, and revised the manuscript. All authors reviewed results and commented on the manuscript.

                Corresponding author: Kevin R. King, MD, PhD, University of California San Diego, 9500 Gilman Dr. MC 0412, La Jolla, CA 92093, Tel: 617-869-9339, krking@ 123456ucsd.edu
                Article
                NIHMS907700
                10.1038/nm.4428
                6477926
                29106401
                17964b7e-c54a-4a62-8db6-c51d68c783d4

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Medicine
                Medicine

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content528

                Cited by253

                Most referenced authors1,399